Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Aleshin

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
BMJ Open|May 31, 2022
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumoursPashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, et al.
American Journal of Physiology. Heart and Circulatory Physiology|February 5, 2008
RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine modelAlexey Aleshin, Radha Ananthakrishnan, Qing Li, et al.
BMJ Open|September 25, 2021
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancerPashtoon Murtaza Kasi, Sarah Sawyer, Jessica Guilford, et al.
Cancer Science|May 1, 2021
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancerHiroya Taniguchi, Yoshiaki Nakamura, Daisuke Kotani, et al.
The Oncologist|July 16, 2024
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinomaAndres F Correa, Ekaterina Kalashnikova, Hsin-Ta Wu, et al.
Molecular Oncology|November 25, 2022
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumabMaya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 5, 2026
The landscape of genomic and socioeconomic variables in colorectal cancer patients based on genetic ancestryPreethi Srinivasan, Sara L Bristow, Fernando L Mendez, et al.
Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
International Journal of Molecular Sciences|October 14, 2022
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical ResectionSara Lonardi, Halla Nimeiri, Chang Xu, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
BMJ Open|May 31, 2022
BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumoursPashtoon Murtaza Kasi, Sakti Chakrabarti, Sarah Sawyer, et al.
American Journal of Physiology. Heart and Circulatory Physiology|February 5, 2008
RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine modelAlexey Aleshin, Radha Ananthakrishnan, Qing Li, et al.
BMJ Open|September 25, 2021
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancerPashtoon Murtaza Kasi, Sarah Sawyer, Jessica Guilford, et al.
Cancer Science|May 1, 2021
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancerHiroya Taniguchi, Yoshiaki Nakamura, Daisuke Kotani, et al.
The Oncologist|July 16, 2024
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinomaAndres F Correa, Ekaterina Kalashnikova, Hsin-Ta Wu, et al.
Molecular Oncology|November 25, 2022
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumabMaya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 5, 2026
The landscape of genomic and socioeconomic variables in colorectal cancer patients based on genetic ancestryPreethi Srinivasan, Sara L Bristow, Fernando L Mendez, et al.
Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
International Journal of Molecular Sciences|October 14, 2022
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical ResectionSara Lonardi, Halla Nimeiri, Chang Xu, et al.
Pageof 7